Company news

Aytu BioPharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

February 9, 2021

Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients

December 27, 2020

Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

December 14, 2020

Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million

December 9, 2020

Aytu BioScience Announces $10.0 Million Bought Deal Offering

December 9, 2020

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

December 9, 2020

Aytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year

November 11, 2020

Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020

November 4, 2020

Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year

October 5, 2020

Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020

October 4, 2020

Aytu BioScience to Reschedule Fourth Quarter and FY 2020 Conference Call

September 22, 2020

Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020

September 15, 2020

Aytu BioScience Announces Global Agreement to Distribute Pinnacle IVD Corporation's 15-Minute COVID-19 Antigen Test

September 7, 2020

Aytu BioScience Announces Launch of Nationwide Mobile COVID-19 Testing Initiative

August 18, 2020

Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study

August 16, 2020

Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration

July 29, 2020

Aytu BioScience Announces Expansion of NATESTO(R) U.S. Commercial Team

July 19, 2020

Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States

July 9, 2020

Aytu BioScience Announces Results from a National Cancer Institute Evaluation of the Company’s Licensed COVID-19 IgG/IgM Rapid Test

June 8, 2020

Aytu BioScience Set to Join Russell 3000(R) Index

June 7, 2020

Aytu BioScience Announces Significant Improvement in Natesto(R) Patient Access in the United States

June 2, 2020

Aytu BioScience Announces Emergency Use Authorization of COVID-19 IgG/IgM Rapid Test

May 31, 2020

Aytu BioScience Announces $15 Million Debt Retirement

May 31, 2020

Aytu BioScience Reports Third Quarter Fiscal 2020 Financial Results

May 13, 2020

Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update

May 6, 2020

Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test

April 29, 2020

Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment

April 26, 2020

Aytu BioScience Announces Results from Annual Stockholders Meeting

April 23, 2020

Aytu BioScience Announces Exclusive Distribution Agreement for COVID-19 IgG/IgM Rapid Test with Singapore-Based Biolidics Limited

April 22, 2020

Aytu BioScience Announces Publication of Results from Natesto Spermatogenesis Study in Journal of Urology

April 20, 2020

Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment

April 19, 2020

Aytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests

April 16, 2020

Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care Rapid Test

April 15, 2020

Aytu BioScience Provides Update on its Licensed COVID-19 IgG/IgM Rapid Test Supply and Ongoing U.S. Distribution

April 14, 2020

Aytu BioScience Consumer Health Subsidiary Launches Regoxidine(R), an FDA Approved Hair Regrowth Treatment Foam that Contains 5% Minoxidil and Targets Over 11 Million U.S. Consumers Who Purchased Hair Regrowth Products in 2019

April 12, 2020

Aytu BioScience Announces Updated Annual Shareholder Meeting Date and Virtual Room Access

April 8, 2020

Aytu BioScience Announces Exclusive ZolpiMist(TM) License to Commercialize Aytu's Oral Spray Sleep Aid in South Korea

April 7, 2020

Aytu BioScience Receives $23.0 Million from Warrant Exercises

April 6, 2020

Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test

April 2, 2020

Aytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order

March 31, 2020

AYTU Announces Delay of Annual Meeting of Stockholders Due to Colorado's "Shelter in Place" Order Related to the COVID-19 Crisis

March 29, 2020

Aytu BioScience Regains Compliance with NASDAQ Minimum Bid Price Requirement

March 24, 2020

Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test

March 22, 2020

Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico

March 18, 2020

Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market

March 18, 2020

Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy

March 16, 2020

Aytu BioScience Establishes COVID-19 IgG/IgM Rapid Test Product Inquiry Procedure for Healthcare Professionals and Institutions

March 12, 2020

Aytu Announces $9.0 Million Registered Direct Offering Priced At-the-Market

March 10, 2020

Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test

March 9, 2020

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals

February 17, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.